17-101-103. Applicability to pharmacists.

Arkansas Code — all titles (historical 2020) · legal_authorities

17-101-103. Applicability to pharmacists. This chapter does not apply to any person licensed under § 17-92-101 et seq.

Source: Arkansas Code — historical release 78 (November 6, 2020) · 17-101-103

Stored review status: Historical 2020-11-06 source release; later amendments not reconciled; machine-extracted, not independently legally reviewed; source heading status: text_in_historical_source. A text match is a research starting point; applicability is not established.

Stored source content

Cross-references

Connections may be documented source relationships, shared citations or nearby passages. Each explains its basis; a connection alone does not establish applicability to your situation.

Arkansas Code — all titles (historical 2020) · legal_authorities

17-92-101. Definitions.

17-92-101. Definitions. As used in this chapter: (1) “Biological product” means a biological product as defined by 42 U.S.C. § 262(i)(1), as it existed on January 1, 2019; (2) “Credentialing” means the issuance of or approval by the Arkansas State Board of Pharmacy of a credential issued to a pharmacist by an agency approved by the Arkansas State Board of Pharmacy certifying that the pharmacist has met the standards of competency established by the Arkansas State Board of Pharmacy for disease state management or other pharmacy services necessitating a credential; (3) “Dentist” means a practitioner of dentistry duly licensed under the laws of this or some other state; (4)(A) “Disease state management” means a strategy that utilizes a team-oriented, multidisciplinary approach to improve healthcare outcomes and quality of care, and when possible, to control healthcare cost through management of targeted chronic disease states. (B) Disease state management focuses on improving health care from prevention to diagnosis and treatment to ongoing follow-up. (C) Disease state management will involve, but not be limited to, patient education, self-care techniques, and outpatient drug therapy management pursuant to a patient care plan; (5) “Drug” shall include all medicines and preparations recognized in the United States Pharmacopeia or the National Formulary as substances intended to be used for the care, mitigation, or prevention of disease of either man or other animals; (6) “Generically equivalent” means a drug that is pharmaceutically and therapeutically equivalent to the drug prescribed; (7) “Interchangeable biological product” means a biological product that is interchangeable as defined by 42 U.S.C. § 262(i)(3), as it existed on January 1, 2019; (8)(A)

Source: Arkansas Code — historical release 78 (November 6, 2020) · 17-92-101

Stored review status: Historical 2020-11-06 source release; later amendments not reconciled; machine-extracted, not independently legally reviewed; source heading status: text_in_historical_source. The source passage cites 17-92-101. This identifies an authority to review, not proof of applicability.